Business Standard

Sun Pharmaceutical gets four observations for Halol facility in Gujarat

The regulator has also observed that lab control mechanisms were not documented

Drugs, Pharma, medicine
Premium

Vinay Umarji Ahmedabad
India’s leading drug maker Sun Pharmaceutical Industries has received four observations for its Halol facility in Gujarat following an inspection by the US Food and Drug Administration (USFDA).

The USFDA has flagged that the facility is not following procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 

The regulator has also observed that lab control mechanisms were not documented, design plans not adequately established, and the processes whose results could not be fully verified by subsequent inspection were not adequately validated. 

Sun Pharma has said it will respond to the observations soon. “Sun Pharma
Topics : Sun Pharma

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in